COVID-19 Clinical Trial
Official title:
Almitrine and Severe COVID-19 Patients in ICU [Almitrine et Patients COVID-19 en Reanimation (French)]
In severe COVID-19 pulmonary failure, the profound hypoxemia is mainly related to pulmonary
vasodilation with altered hypoxic pulmonary vasoconstriction (HPV). Besides prone
positioning, other non-ventilatory strategies may reduce the intrapulmonary shunt. This study
has investigated almitrine, a pharmacological option used in standard care to improve
oxygenation.
A case control series of mechanically ventilated confirmed COVID-19 patients was recorded.
At stable ventilatory settings, consecutive patients received two doses of almitrine (4 and
12 mcg/kg/min) at 30-45 min interval each, and were compared to 7 "control" COVID-matched
patients conventionally treated.
The end-point was the reduction of intra-pulmonary shunt, with an increase in partial
pressure of arterial oxygen (PaO2) and central venous oxygen saturation (ScvO2).
The clinical presentation of COVID-19 disease is heterogenous, ranging from no symptoms to
severe acute respiratory failure (ARF), which may have a poor prognosis. A severe hypoxemia
is associated with preserved respiratory mechanical properties, in particular the pulmonary
system compliance.
The hypoxia during the early phase seems to mainly result from an important
ventilation/perfusion (VA/Q) mismatch associated with an altered pulmonary vasoconstriction.
The "protective" mechanism called hypoxic pulmonary vasoconstriction (HPV) normally reduces
the blood flow in poorly or non-ventilated areas towards aerated zones leading to reduce the
(VA/Q) mismatch. HPV seems poorly functional in COVID-19 severe patients in absence of "cor
pulmonale".
According to the French National agency for Drug Security (ANSM, Paris, France), only iv
almitrine is indicated for hypoxic acute respiratory failure as Drug of Major Therapeutic
Interest. This molecule is a routine option in the treatment strategy of severe hypoxemia.
The investigators studied COVID-19 patients mechanically ventilated at FiO2 1 with a severe
intrapulmonary shunt during their early phase. The emergency conditions and the acute high
inflow of patients to ICU impeded the design of a randomized control trial. To eliminate the
eventuality of a spontaneous evolution of hypoxia, these patients will be compared with
control-matched COVID patients treated conventionally.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
| Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
| Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
| Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
| Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
| Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
| Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
| Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
| Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
| Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
| Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
| Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
| Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
| Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
| Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
| Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
| Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
| Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|